# Adhesive bioactive materials in ocular applications: Toward smart, regenerative, and minimally invasive therapies

**Authors:** Yifei Niu, Saiqun Li, Fei Yu, Xuan Zhao, Jin Yuan

PMC · DOI: 10.1016/j.bioactmat.2025.12.004 · 2025-12-12

## TL;DR

This review explores adhesive bioactive materials for eye treatments, focusing on their potential for smart, regenerative, and minimally invasive therapies.

## Contribution

The paper introduces a comprehensive synthesis of design strategies and future directions for ocular adhesive bioactive materials.

## Key findings

- Adhesive materials are being developed for sutureless ophthalmic surgery with improved biocompatibility.
- Biomimetic design principles enhance integration and therapeutic effectiveness in ocular applications.
- Combining adhesives with regenerative therapies enables active tissue regeneration beyond structural support.

## Abstract

Ocular adhesive bioactive materials represent a paradigm shift in ophthalmic surgery and tissue repair, offering sutureless solutions with enhanced biocompatibility, reduced complications, and improved clinical outcomes. Designed to function as sealants, defect fillers, and delivery vehicles for drugs or cells, these materials must meet the stringent physiological and optical demands of the ocular environment. They are typically classified by anatomical application (ocular surface vs. fundus) and material origin (natural vs. synthetic), and rely on diverse crosslinking strategies to achieve tailored mechanical and adhesive properties. Current design approaches increasingly embrace biomimetic principles—aiming to replicate the structural and functional characteristics of native ocular tissues—to improve integration and therapeutic effectiveness. Moreover, the combination of adhesive materials with regenerative therapies such as stem cells, and exosomes extends their potential from simple structural support to active tissue regeneration. This review provides a comprehensive synthesis of ocular adhesive bioactive materials, outlines major design strategies and applications, and highlights future directions toward personalized and programmable regenerative platforms capable of addressing complex ophthalmic challenges.

Image 1

•Integrates adhesion mechanisms, crosslinking strategies, and ocular applications.•Emphasizes repair-synchronized biodegradation and optical/photochemical safety.•Expands from sealants to regenerative scaffolds with drug/cell delivery functions.•Summarizes advances in wet adhesion, hierarchical networks, and microstructuring•Outlines future directions: personalized printing, exosome/stem cell integration.

Integrates adhesion mechanisms, crosslinking strategies, and ocular applications.

Emphasizes repair-synchronized biodegradation and optical/photochemical safety.

Expands from sealants to regenerative scaffolds with drug/cell delivery functions.

Summarizes advances in wet adhesion, hierarchical networks, and microstructuring

Outlines future directions: personalized printing, exosome/stem cell integration.

## Full-text entities

- **Genes:** F13A1 (coagulation factor XIII A chain) [NCBI Gene 2162] {aka F13A}, CCN2 (cellular communication network factor 2) [NCBI Gene 1490] {aka CTGF, HCS24, IBP-8, IGFBP8, KMD, NOV2}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, MIR182 (microRNA 182) [NCBI Gene 406958] {aka MIRN182, miRNA182, mir-182}, MIR432 (microRNA 432) [NCBI Gene 574451] {aka MIRN432, hsa-mir-432, mir-432}, RHC [NCBI Gene 3057], F13B (coagulation factor XIII B chain) [NCBI Gene 2165] {aka FXIIIB}, ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58] {aka ACTA, ASMA, CFTD, CFTD1, CFTDM, CMYO2A}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, PVR (PVR cell adhesion molecule) [NCBI Gene 5817] {aka CD155, HVED, NECL5, Necl-5, PVS, TAGE4}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, ETFA (electron transfer flavoprotein subunit alpha) [NCBI Gene 2108] {aka EMA, GA2, MADD}, CNTF (ciliary neurotrophic factor) [NCBI Gene 1270] {aka HCNTF}, RPE65 (retinoid isomerohydrolase RPE65) [NCBI Gene 6121] {aka BCO3, LCA2, RP20, mRPE65, p63, rd12}, PLG (plasminogen) [NCBI Gene 5340] {aka HAE4}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, TJP1 (tight junction protein 1) [NCBI Gene 7082] {aka ZO-1}, PRSS3 (serine protease 3) [NCBI Gene 5646] {aka MTG, PRSS4, T9, TRY3, TRY4}, LAP (Laryngeal adductor paralysis) [NCBI Gene 7939], POU4F2 (POU class 4 homeobox 2) [NCBI Gene 5458] {aka BRN3.2, BRN3B, Brn-3b}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MMRN1 (multimerin 1) [NCBI Gene 22915] {aka ECM, EMILIN4, GPIa*, MMRN}, MAP3K3 (mitogen-activated protein kinase kinase kinase 3) [NCBI Gene 4215] {aka CCM5, MAPKKK3, MEKK3}, PLA2G1B (phospholipase A2 group IB) [NCBI Gene 5319] {aka PLA2, PLA2A, PPLA2}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, TRAM2 (translocation associated membrane protein 2) [NCBI Gene 9697], ALB (albumin) [NCBI Gene 280717], MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}
- **Diseases:** burns (MESH:D002056), MHs (MESH:D012167), stem cell deficiency (MESH:D000092423), spinal disorders (MESH:D013118), MD (MESH:C535955), MVB (MESH:D001835), macular detachment (MESH:D012163), ocular injuries (MESH:D005131), papillary conjunctivitis (MESH:D003233), conjunctival defect (MESH:D003229), phototoxicity (MESH:D017484), staphyloma (MESH:C536352), pterygium (MESH:D011625), AIDS (MESH:D000163), edema (MESH:D004487), myopia (MESH:D009216), AHTL (MESH:C537113), AMD (MESH:D008268), ischemic (MESH:D002545), Proliferative vitreoretinopathy (MESH:D018630), Descemet's stripping (MESH:D010300), neovascularization (MESH:D016510), vascular occlusion (MESH:D008641), open globe injuries (MESH:D006259), APCS (MESH:D003316), vision loss (MESH:D014786), corneal fibrosis (MESH:D005355), battlefield injuries (MESH:D014947), penetrating eye injuries (MESH:D015807), inflammation (MESH:D007249), necrosis (MESH:D009336), leukoplakia (MESH:D007971), posterior segment diseases (MESH:C537538), visual field defects (MESH:D005128), corneal ulcers (MESH:D003320), CMHA-S (MESH:D018455), retinal damage (MESH:D012164), allergies (MESH:D004342), hepatitis (MESH:D056486), glaucoma (MESH:D005901), corneal perforation (MESH:D057112), astigmatism (MESH:D001251), ocular hypertension (MESH:D009798), PMOA (MESH:C537734), Descemet's membrane (MESH:D015433), cataract (MESH:D002386), RRD (MESH:C563710), collagen (MESH:D003095), epithelial hyperplasia (MESH:D017573), retinal degeneration (MESH:D012162), chorioretinal (MESH:D002825), leak (MESH:D019559), alkali burns (MESH:D006934), cytotoxicity (MESH:D064420), RPC (MESH:D012173), corneal stromal defect (MESH:D003317), DR (MESH:D003930), coagulopathies (MESH:D001778), infection (MESH:D007239), SB (MESH:D015422)
- **Chemicals:** 1,4-Butanediol diglycidyl ether (MESH:C014376), HA (MESH:D006820), aldehyde (MESH:D000447), 4-Pentenoate (MESH:C009785), ethanol (MESH:D000431), TEA (MESH:C009546), HPA (MESH:C005434), acetic acid (MESH:D019342), erythrosin B (MESH:D004923), kynurenine (MESH:D007737), Ge (MESH:D005857), carboxymethyl CS (MESH:C514968), calcium chloride (MESH:D002122), PDA (MESH:C568283), DuraSeal (MESH:C030189), carbodiimide (MESH:D002234), cinnamic acid (MESH:C029010), catechol (MESH:C034221), methylene blue (MESH:D008751), methylcellulose (MESH:D008747), hydrazone (MESH:D006835), silicone oil (MESH:D012827), E (MESH:D004540), N-hydroxysuccinimide (MESH:C001426), amide (MESH:D000577), Schiff base (MESH:D012545), GMA (MESH:C007870), tyrosine (MESH:D014443), water (MESH:D014867), DVS (MESH:C009873), Cyanoacrylate (MESH:D003487), polymer (MESH:D011108), ester (MESH:D004952), chitin (MESH:D002686), hydrazine (MESH:C029424), PEG (MESH:D011092), EDTA (MESH:D004492), Azide (MESH:D001386), DAD (MESH:C025953), Polysaccharide (MESH:D011134), alginate (MESH:D000464), phalloidin (MESH:D010590), formic acid (MESH:C030544), salt (MESH:D012492), CS (MESH:D048271), T (MESH:D014316), chondroitin sulfate (MESH:D002809), acrylate (MESH:C036658), Saline (MESH:D012965), PEGDA (MESH:C437167), metal (MESH:D008670), alkyne (MESH:D000480), ROS (MESH:D017382), formaldehyde (MESH:D005557), DAPI (MESH:C007293), gadolinium oxide (MESH:C030581), sebacoyl chloride (MESH:C061659), dendrimers (MESH:D050091), epoxide (MESH:D004852), heparin (MESH:D006493)
- **Species:** Sus scrofa (pig, species) [taxon 9823], Legionella sp. I (species) [taxon 66967], Mus musculus (house mouse, species) [taxon 10090], Pseudomonas aeruginosa (species) [taxon 287], Halosbaena sp. PL (species) [taxon 1904765], Bos taurus (bovine, species) [taxon 9913], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HA — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_D044), G-SH — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_W974), RPE — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_IQ82)

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12765266/full.md

---
Source: https://tomesphere.com/paper/PMC12765266